临床使用相关的耐万古霉素屎肠球菌对利奈唑胺敏感性降低：与奎奴普丁-达福普汀的比较
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
作者信息
Raad Issam I, Hanna Hend A, Hachem Ray Y, Dvorak Tanya, Arbuckle Rebecca B, Chaiban Gassan, Rice Louis B
机构信息
Department of Infectious Diseases, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
出版信息
Antimicrob Agents Chemother. 2004 Sep;48(9):3583-5. doi: 10.1128/AAC.48.9.3583-3585.2004.
Abstract
The susceptibility of 135 vancomycin-resistant Enterococcus faecium bacteremic isolates to linezolid and quinupristin-dalfopristin was determined. All were susceptible to linezolid, while 88% were susceptible to quinupristin-dalfopristin prior to the clinical use of the drugs at our hospital. More than 6 months after their clinical use, a decrease in susceptibility was noted for only linezolid at 83%. This was related in part to a single G2576U gene mutation in domain V of the 23S rRNA gene.
摘要
测定了135株耐万古霉素屎肠球菌血流感染分离株对利奈唑胺和奎奴普丁-达福普汀的敏感性。所有菌株对利奈唑胺均敏感，而在我院临床使用这些药物之前，88%的菌株对奎奴普丁-达福普汀敏感。在临床使用超过6个月后，仅观察到利奈唑胺的敏感性有所下降，降至83%。这部分与23S rRNA基因V结构域中的单个G2576U基因突变有关。
相似文献
1
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.临床使用相关的耐万古霉素屎肠球菌对利奈唑胺敏感性降低：与奎奴普丁-达福普汀的比较
Antimicrob Agents Chemother. 2004 Sep;48(9):3583-5. doi: 10.1128/AAC.48.9.3583-3585.2004.
2
Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.万古霉素耐药屎肠球菌分离株在治疗期间对利奈唑胺的敏感性变化：1例病例报告
J Antimicrob Chemother. 2005 Oct;56(4):787-9. doi: 10.1093/jac/dki318. Epub 2005 Sep 5.
3
Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.奎奴普丁-达福普汀与利奈唑胺治疗耐万古霉素屎肠球菌菌血症的疗效及耐药性发展
Scand J Infect Dis. 2010 Jul;42(6-7):491-9. doi: 10.3109/00365541003699623.
4
Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.在未预先接触过利奈唑胺的患者中发生的耐利奈唑胺、耐万古霉素屎肠球菌感染。
Clin Infect Dis. 2003 Jun 1;36(11):E146-8. doi: 10.1086/374929. Epub 2003 May 20.
5
In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.利奈唑胺与奎奴普丁/达福普汀对革兰氏阳性球菌的体外活性。
Indian J Med Res. 2004 Dec;120(6):546-52.
6
Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis.某大学医院中耐万古霉素和利奈唑胺屎肠球菌的定植：分子流行病学及危险因素分析
Int J Antimicrob Agents. 2009 Feb;33(2):137-42. doi: 10.1016/j.ijantimicag.2008.08.017. Epub 2008 Nov 13.
7
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.一项前瞻性随机研究，比较奎奴普丁-达福普汀与利奈唑胺治疗耐万古霉素屎肠球菌感染的疗效。
J Antimicrob Chemother. 2004 Apr;53(4):646-9. doi: 10.1093/jac/dkh144. Epub 2004 Mar 3.
8
Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage.耐万古霉素屎肠球菌多位点序列分型C1流行谱系中利奈唑胺耐药性的出现。
J Clin Microbiol. 2006 Mar;44(3):1153-5. doi: 10.1128/JCM.44.3.1153-1155.2006.
9
Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium.重症监护病房中耐(linezolid)利奈唑烷(Enterococcus faecalis)肠球菌和屎肠球菌的多个克隆株的传播。
J Antimicrob Chemother. 2012 Aug;67(8):1819-23. doi: 10.1093/jac/dks146. Epub 2012 Apr 24.
10
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.达托霉素、利奈唑胺和奎奴普丁/达福普汀对某大型癌症中心革兰氏阳性菌分离株的体外活性比较
Diagn Microbiol Infect Dis. 2005 Jul;52(3):255-9. doi: 10.1016/j.diagmicrobio.2005.02.015.
引用本文的文献
1
Linezolid Resistance Genes and Mutations among Linezolid-Susceptible spp.-A Loose Cannon?利奈唑胺敏感菌中的利奈唑胺耐药基因与突变——一个难以控制的因素？
Antibiotics (Basel). 2024 Jan 19;13(1):101. doi: 10.3390/antibiotics13010101.
2
The Increasing Issue of Vancomycin-Resistant Enterococci and the Bacteriocin Solution.万古霉素耐药肠球菌日益严重的问题与细菌素解决方案。
Probiotics Antimicrob Proteins. 2020 Sep;12(3):1203-1217. doi: 10.1007/s12602-019-09618-6.
3
Characterization of Vancomycin Resistant Enterococci in Hospitalized Patients and Role of Gut Colonization.住院患者中耐万古霉素肠球菌的特征及肠道定植的作用
J Clin Diagn Res. 2017 Sep;11(9):DC01-DC05. doi: 10.7860/JCDR/2017/25988.10548. Epub 2017 Sep 1.
4
Antimicrobial susceptibility pattern of vancomycin resistant enterococci to newer antimicrobial agents.耐万古霉素肠球菌对新型抗菌药物的药敏模式
Indian J Med Res. 2015 Apr;141(4):483-6. doi: 10.4103/0971-5916.159309.
5
Saponins increase susceptibility of vancomycin-resistant enterococci to antibiotic compounds.皂苷可增加耐万古霉素肠球菌对抗生素化合物的敏感性。
Eur J Microbiol Immunol (Bp). 2014 Dec;4(4):204-12. doi: 10.1556/EUJMI-D-14-00029. Epub 2014 Dec 16.
6
Virulence of vancomycin-resistant Enterococcus faecium according to linezolid resistance and clinical outbreak status.利奈唑胺耐药和临床暴发状态的粪肠球菌万古霉素耐药株的毒力。
Antimicrob Agents Chemother. 2013 Aug;57(8):3923-7. doi: 10.1128/AAC.00192-13. Epub 2013 Jun 3.
7
Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium.替加环素单药与联合庆大霉素治疗利奈唑胺耐药粪肠球菌性实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2013 Jul;57(7):3392-4. doi: 10.1128/AAC.00646-13. Epub 2013 Apr 15.
8
Intrinsic and acquired resistance mechanisms in enterococcus.肠球菌固有和获得性耐药机制。
Virulence. 2012 Aug 15;3(5):421-33. doi: 10.4161/viru.21282.
9
Resistance to linezolid caused by modifications at its binding site on the ribosome.核糖体结合部位修饰导致对利奈唑胺的耐药性。
Antimicrob Agents Chemother. 2012 Feb;56(2):603-12. doi: 10.1128/AAC.05702-11. Epub 2011 Dec 5.
10
Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline.婴儿期耐万古霉素粪肠球菌性脑膜炎：该病原体的特征及脑室注射达托霉素联合静脉注射替加环素的成功治疗。
Pediatr Infect Dis J. 2010 Apr;29(4):379-81. doi: 10.1097/INF.0b013e3181c806d8.
本文引用的文献
1
Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.重组能力影响粪肠球菌对利奈唑胺的突变耐药频率和位点。
Antimicrob Agents Chemother. 2003 Oct;47(10):3318-20. doi: 10.1128/AAC.47.10.3318-3320.2003.
2
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.利奈唑胺用于治疗多重耐药革兰氏阳性菌感染：来自同情用药项目的经验。
Clin Infect Dis. 2003 Jan 15;36(2):159-68. doi: 10.1086/345744. Epub 2003 Jan 3.
3
Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.粪肠球菌和屎肠球菌中的基因剂量与利奈唑胺耐药性
Antimicrob Agents Chemother. 2002 Oct;46(10):3334-6. doi: 10.1128/AAC.46.10.3334-3336.2002.
4
Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.用奎奴普丁/达福普汀治疗耐万古霉素屎肠球菌感染。
Clin Infect Dis. 2001 Dec 1;33(11):1816-23. doi: 10.1086/323899. Epub 2001 Oct 19.
5
Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.免疫功能低下宿主中耐万古霉素肠球菌感染的治疗：奎奴普丁-达福普汀联合米诺环素。
Antimicrob Agents Chemother. 2001 Nov;45(11):3202-4. doi: 10.1128/AAC.45.11.3202-3204.2001.
6
Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.对利奈唑胺的耐药性：rRNA中突变的特征及其在耐万古霉素肠球菌中的发生率比较
Antimicrob Agents Chemother. 2001 Jul;45(7):2154-6. doi: 10.1128/AAC.45.7.2154-2156.2001.
7
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.耐万古霉素的屎肠球菌对利奈唑胺耐药导致的感染。
Lancet. 2001 Apr 14;357(9263):1179. doi: 10.1016/S0140-6736(00)04376-2.
8
Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.奎奴普丁/达福普汀治疗耐万古霉素屎肠球菌感染。
Clin Infect Dis. 2000 May;30(5):790-7. doi: 10.1086/313766. Epub 2000 May 18.
9
Vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染
N Engl J Med. 2000 Mar 9;342(10):710-21. doi: 10.1056/NEJM200003093421007.
10
Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe.西欧动物、生肉和医院患者分离出的屎肠球菌对奎奴普丁-达福普汀的耐药机制
Antimicrob Agents Chemother. 2000 Feb;44(2):433-6. doi: 10.1128/AAC.44.2.433-436.2000.
Zotero 插件